Regeneron's Covid-19 Antibody Cocktail Had 2021 U.S. Sales Near $6 Billion

By Matt Grossman

Regeneron Pharmaceuticals Inc.'s antibody cocktail for treating Covid-19 generated sales of about $5.82 billion in the U.S. in 2021, Regeneron estimated on Monday.

The Tarrytown, N.Y.-based pharmaceutical company said the preliminary sales figure was based on unaudited fourth-quarter sales of about $2.29 billion for the therapy. Regeneron released the estimate ahead of its appearance at an industry conference later Monday.

Regeneron also estimated that its Eylea injection, used to treat age-related macular degeneration and other eye conditions, accounted for U.S. sales of about $5.79 billion. In the fourth quarter, Eylea sales were about $1.54 billion, Regeneron said.

Write to Matt Grossman at [e-mail]

(END) Dow Jones Newswires

01-10-22 0639ET